p53: 25 Years after its discovery

Trends in Pharmacological Sciences

Volumn 25, Issue 4, 2004, Pages 177-181

  Hofseth, Lorne J ^a,b   Hussain, S Perwez ^a   Harris, Curtis C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; DNA; PROTEIN P53;

APOPTOSIS; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CARCINOGENESIS; CELL AGING; CELL CYCLE; CELL DAMAGE; CELL DIFFERENTIATION; CELL REGENERATION; CELL SURVIVAL; DNA REPAIR; DRUG TARGETING; GENE EXPRESSION; GENE MUTATION; GENETIC CODE; HUMAN; MISSENSE MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; STRESS;

EID: 1942517876     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2004.02.009     Document Type: Short Survey

References (42)

1. Harris C.C. p53 Tumor suppressor gene: from the basic research laboratory to the clinic - an abridged historical perspective. Carcinogenesis. 17:1996;1187-1198.
2. Oren M., Rotter V. Introduction: p53-the first twenty years. Cell. Mol. Life Sci. 55:1999;9-11.
3. DeLeo A.B., et al. Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc. Natl. Acad. Sci. U. S. A. 76:1979;2420-2424.
4. Lane D.P., Crawford L.V. T antigen is bound to a host protein in SV40-transformed cells. Nature. 278:1979;261-263.
5. Linzer D.I., Levine A.J. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell. 17:1979;43-52.
6. Scheffner M., et al. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 63:1990;1129-1136.
7. Sigal A., Rotter V. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res. 60:2000;6788-6793.
8. Greenblatt M.S., et al. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54:1994;4855-4878.
9. Hollstein M., et al. p53 mutations in human cancers. Science. 253:1991;49-53.
10. Levine A.J., et al. The p53 tumour suppressor gene. Nature. 351:1991;453-456.
11. Donehower L.A., et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 356:1992;215-221.
12. Malkin D., et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 250:1990;1233-1238.
13. Srivastava S., et al. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature. 348:1990;747-749.
14. Adimoolam S., Ford J.M. p53 and regulation of DNA damage recognition during nucleotide excision repair. DNA Repair (Amst.). 2:2003;947-954.
15. Offer H., et al. Direct involvement of p53 in the base excision repair pathway of the DNA repair machinery. FEBS Lett. 450:1999;197-204.
16. Zhou J., et al. A role for p53 in base excision repair. EMBO J. 20:2001;914-923.
17. Tyner S.D., et al. p53 mutant mice that display early ageing-associated phenotypes. Nature. 415:2002;45-53.
18. Garcia-Cao I., et al. 'Super p53' mice exhibit enhanced DNA damage response, are tumor resistant and age normally. EMBO J. 21:2002;6225-6235.
19. Kinzler K.W., Vogelstein B. Gatekeepers and caretakers. Nature. 386:1997;761-763.
20. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell. 88:1997;323-331.
21. Raycroft L., et al. Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science. 249:1990;1049-1051.
22. Vousden K.H., Lu X. Live or let die: the cell's response to p53. Nat. Rev. Cancer. 2:2002;594-604.
23. Yin Y., et al. PAC1 phosphatase is a transcription target of p53 in signalling apoptosis and growth suppression. Nature. 422:2003;527-531.
24. Haupt S., et al. Apoptosis - the p53 network. J. Cell Sci. 116:2003;4077-4085.
25. Mihara M., et al. p53 has a direct apoptogenic role at the mitochondria. Mol. Cell. 11:2003;577-590.
26. Flores E.R., et al. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature. 416:2002;560-564.
27. Urist M., Prives C. p53 leans on its siblings. Cancer Cell. 1:2002;311-313.
28. Hussain S.P., Harris C.C. Molecular epidemiology of human cancer: contribution of mutation spectra studies of tumor suppressor genes. Cancer Res. 58:1998;4023-4037.
29. Hussain S.P., et al. Increased p53 mutation load in nontumorous human liver of Wilson disease and hemochromatosis: oxyradical overload diseases. Proc. Natl. Acad. Sci. U. S. A. 97:2000;12770-12775.
30. Kirk G.D., et al. Ser-249 p53 mutations in plasma DNA of patients with hepatocellular carcinoma from The Gambia. J. Natl. Cancer Inst. 92:2000;148-153.
31. Appella E., Anderson C.W. Post-translational modifications and activation of p53 by genotoxic stresses. Eur. J. Biochem. 268:2001;2764-2772.
32. Hofseth L.J., et al. Nitric oxide-induced cellular stress and p53 activation in chronic inflammation. Proc. Natl. Acad. Sci. U. S. A. 100:2003;143-148.
33. Borresen-Dale A.L. TP53 and breast cancer. Hum. Mutat. 21:2003;292-300.
34. Iacopetta B. TP53 mutation in colorectal cancer. Hum. Mutat. 21:2003;271-276.
35. Bykov V.J., et al. Small molecules that reactivate mutant p53. Eur. J. Cancer. 39:2003;1828-1834.
36. Woods Y.L., Lane D.P. Exploiting the p53 pathway for cancer diagnosis and therapy. Hematol. J. 4:2003;233-247.
37. Issaeva N., et al. Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide. Proc. Natl. Acad. Sci. U. S. A. 100:2003;13303-13307.
38. Zhu J., et al. Targeting gene expression to tumor cells with loss of wild-type p53 function. Cancer Gene Ther. 7:2000;4-12.
39. Fojo T. p53 as a therapeutic target: unresolved issues on the road to cancer therapy targeting mutant p53. Drug Resist. Updat. 5:2002;209-216.
40. Weber J.D., et al. Nucleolar Arf sequesters Mdm2 and activates p53. Nat. Cell Biol. 1:1999;20-26.
41. Lu W., et al. Activation of p53 by roscovitine-mediated suppression of MDM2 expression. Oncogene. 20:2001;3206-3216.
42. Haupt Y., et al. Deconstruction of p53 functions and regulation. Oncogene. 21:2002;8223-8231.